Logo Logo
Switch Language to German

Jost, Wolfgang H.; Steffen, Armin and Berweck, Steffen (2021): A critical review of incobotulinumtoxinA in the treatment of chronic sialorrhea in pediatric patients. In: Expert Review of Neurotherapeutics, Vol. 21, No. 10: pp. 1059-1068

Full text not available from 'Open Access LMU'.


Introduction Sialorrhea, also known as hypersalivation, ptyalis, or drooling, results in physical and psychosocial complications that may have a significant negative impact on quality of life for both the patient and their caregiver. The goal of pharmacological treatment is to reduce excessive salivary flow, while maintaining a moist and healthy oral cavity;until recently, however, few of the agents used to treat chronic sialorrhea have been approved in pediatric patients. Areas covered This article summarizes early evidence for the use of botulinum neurotoxin A formulations in the treatment of children/adolescents with chronic sialorrhea, and findings of the recently completed phase III trial of incobotulinumtoxinA in this indication. Alternative therapies are also briefly discussed. Expert opinion IncobotulinumtoxinA is the first botulinum neurotoxin A to be approved for the treatment of chronic sialorrhea in children and adults, following the results of phase III trials that demonstrate the efficacy and safety of the drug in these patients. The authors expect that the positive findings will result in updates to clinical guidelines for the treatment of children with chronic sialorrhea.

Actions (login required)

View Item View Item